It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The inhibitor of κB (IκB) kinase (IKK) is a central regulator of NF-κB signaling. All IKK complexes contain hetero- or homodimers of the catalytic IKKβ and/or IKKα subunits. Here, we identify a YDDΦxΦ motif, which is conserved in substrates of canonical (IκBα, IκBβ) and alternative (p100) NF-κB pathways, and which mediates docking to catalytic IKK dimers. We demonstrate a quantitative correlation between docking affinity and IKK activity related to IκBα phosphorylation/degradation. Furthermore, we show that phosphorylation of the motif’s conserved tyrosine, an event previously reported to promote IκBα accumulation and inhibition of NF-κB gene expression, suppresses the docking interaction. Results from integrated structural analyzes indicate that the motif binds to a groove at the IKK dimer interface. Consistently, suppression of IKK dimerization also abolishes IκBα substrate binding. Finally, we show that an optimized bivalent motif peptide inhibits NF-κB signaling. This work unveils a function for IKKα/β dimerization in substrate motif recognition.
The inhibitor of kB kinase (IKK) is a central regulator of NF-kB signalling. Here the authors identify a motif conserved in substrates of canonical and alternative NF-kB pathways which mediates docking to catalytic IKK dimers: they show that phosphorylation of the conserved tyrosine suppresses the docking interaction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Boulevard Sébastien Brant, Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR7242), Ecole Superieure de Biotechnologie de Strasbourg, Illkirch, France (GRID:grid.418692.0) (ISNI:0000 0004 0610 0264)
2 CHU, Laboratory of Cancer Biology, GIGA Cancer, University of Liege, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
3 Technische Universität Berlin, Institute of Biotechnology, Berlin, Germany (GRID:grid.6734.6) (ISNI:0000 0001 2292 8254)
4 Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) / INSERM UMR-S 1258 / CNRS UMR7104/ Université de Strasbourg, Illkirch, France (GRID:grid.420255.4) (ISNI:0000 0004 0638 2716)
5 CNRS UPR9002, Institut Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France (GRID:grid.465534.5) (ISNI:0000 0004 0638 0833)
6 The Institute of Cancer Research, Division of Cancer Biology, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1499 0189)
7 CHU, Laboratory of Cancer Biology, GIGA Cancer, University of Liege, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253); WEL Research Institute, WELBIO department, Wavre, Belgium (GRID:grid.509491.0)